Institution
New York Methodist Hospital
Healthcare•Brooklyn, New York, United States•
About: New York Methodist Hospital is a healthcare organization based out in Brooklyn, New York, United States. It is known for research contribution in the topics: Myocardial infarction & Percutaneous coronary intervention. The organization has 948 authors who have published 936 publications receiving 29954 citations.
Topics: Myocardial infarction, Percutaneous coronary intervention, Population, Conventional PCI, Heart failure
Papers published on a yearly basis
Papers
More filters
••
University of Michigan1, Harvard University2, National Institutes of Health3, University of Minnesota4, Universidade Federal do Rio Grande do Sul5, Russian National Research Medical University6, New York Methodist Hospital7, Université de Montréal8, University of Washington9, Northwestern University10, University of Wisconsin-Madison11
TL;DR: In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.
Abstract: Background Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction. Methods In this randomized, double-blind trial, we assigned 3445 patients with symptomatic heart failure and a left ventricular ejection fraction of 45% or more to receive either spironolactone (15 to 45 mg daily) or placebo. The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. Results With a mean follow-up of 3.3 years, the primary outcome occurred in 320 of 1722 patients in the spironolactone group (18.6%) and 351 of 1723 patients in the placebo group (20.4%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.77 to 1.04; P = 0.14). Of the components of the primary outcome, only hospitalization for heart failure had a significantly lower incidence in the spironolactone group than in the placebo group (206 patients [12.0%] vs. 245 patients [14.2%]; hazard ratio, 0.83; 95% CI, 0.69 to 0.99, P = 0.04). Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone. Treatment with spiron olactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) but reduced hypokalemia. With frequent monitoring, there were no significant differences in the incidence of serious adverse events, a serum creatinine level of 3.0 mg per deciliter (265 μmol per liter) or higher, or dialysis. Conclusions In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. (Funded by the National Heart, Lung, and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.)
1,930 citations
••
TL;DR: A treatment protocol that included matched transfusions, bronchodilators, and bronchoscopy was evaluated and it was found that infection and fat embolism are underdiagnosed in patients with the syndrome.
Abstract: Background The acute chest syndrome is the leading cause of death among patients with sickle cell disease. Since its cause is largely unknown, therapy is supportive. Pilot studies with improved diagnostic techniques suggest that infection and fat embolism are underdiagnosed in patients with the syndrome. Methods In a 30-center study, we analyzed 671 episodes of the acute chest syndrome in 538 patients with sickle cell disease to determine the cause, outcome, and response to therapy. We evaluated a treatment protocol that included matched transfusions, bronchodilators, and bronchoscopy. Samples of blood and respiratory tract secretions were sent to central laboratories for antibody testing, culture, DNA testing, and histopathological analyses. Results Nearly half the patients were initially admitted for another reason, mainly pain. When the acute chest syndrome was diagnosed, patients had hypoxia, decreasing hemoglobin values, and progressive multilobar pneumonia. The mean length of hospitalization was 10....
1,024 citations
••
Mayo Clinic1, University of Pittsburgh2, Autonomous University of Barcelona3, University of Alberta4, Karolinska University Hospital5, University of Florida6, New York Methodist Hospital7, United States Department of Veterans Affairs8, George Washington University9, University of Duisburg-Essen10, Albert Einstein College of Medicine11, Virginia Commonwealth University12, Otto-von-Guericke University Magdeburg13, Vrije Universiteit Brussel14, Ghent University Hospital15, Hospital of the University of Pennsylvania16, University of Chicago17, Duke University18, University of Maryland, Baltimore19, RWTH Aachen University20, St. John Providence Health System21, University of California, San Diego22, St Thomas' Hospital23, Beth Israel Deaconess Medical Center24, Medical University of Vienna25, Tampa General Hospital26, Goethe University Frankfurt27
TL;DR: Two novel markers for AKI have been identified and validated in independent multicenter cohorts and are superior to existing markers, provide additional information over clinical variables and add mechanistic insight into AKI.
Abstract: Introduction: Acute kidney injury (AKI) can evolve quickly and clinical measures of function often fail to detect AKI at a time when interventions are likely to provide benefit. Identifying early markers of kidney damage has been difficult due to the complex nature of human AKI, in which multiple etiologies exist. The objective of this study was to identify and validate novel biomarkers of AKI. Methods: We performed two multicenter observational studies in critically ill patients at risk for AKI - discovery and validation. The top two markers from discovery were validated in a second study (Sapphire) and compared to a number of previously described biomarkers. In the discovery phase, we enrolled 522 adults in three distinct cohorts including patients with sepsis, shock, major surgery, and trauma and examined over 300 markers. In the Sapphire validation study, we enrolled 744 adult subjects with critical illness and without evidence of AKI at enrollment; the final analysis cohort was a heterogeneous sample of 728 critically ill patients. The primary endpoint was moderate to severe AKI (KDIGO stage 2 to 3) within 12 hours of sample collection. Results: Moderate to severe AKI occurred in 14% of Sapphire subjects. The two top biomarkers from discovery were validated. Urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), both inducers of G1 cell cycle arrest, a key mechanism implicated in AKI, together demonstrated an AUC of 0.80 (0.76 and 0.79 alone). Urine [TIMP-2]·[IGFBP7] was significantly superior to all previously described markers of AKI (P 0.72. Furthermore, [TIMP2]·[IGFBP7] significantly improved risk stratification when added to a nine-variable clinical model when analyzed using Cox proportional hazards model, generalized estimating equation, integrated discrimination improvement or net reclassification improvement. Finally, in sensitivity analyses [TIMP-2]·[IGFBP7] remained significant and superior to all other markers regardless of changes in reference creatinine method.
997 citations
••
Boston University1, University of Mississippi2, Howard University3, University of Miami4, Thomas Jefferson University5, Georgia Regents University6, University of North Carolina at Chapel Hill7, New York Methodist Hospital8, University of Toronto9, Emory University10, Rutgers University11, Mount Sinai St. Luke's and Mount Sinai Roosevelt12, University of Alabama13, Virginia Commonwealth University14, University of Pittsburgh15, Duke University16, University of Illinois at Chicago17, Children's Hospital Oakland Research Institute18, University of California, San Francisco19, National Institutes of Health20
TL;DR: In a long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Patients with Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine whether hydroxyuraxurea attenuates mortality in Patients With SCA as discussed by the authors.
Abstract: ContextHydroxyurea increases levels of fetal hemoglobin (HbF)
and decreases morbidity from vaso-occlusive complications in patients
with sickle cell anemia (SCA). High HbF levels reduce morbidity and
mortality.ObjectiveTo determine whether hydroxyurea attenuates mortality in
patients with SCA.DesignLong-term observational follow-up study of mortality in
patients with SCA who originally participated in the randomized,
double-blind, placebo-controlled Multicenter Study of Hydroxyurea in
Sickle Cell Anemia (MSH), conducted in 1992-1995, to
determine if hydroxyurea reduces vaso-occlusive events. In the MSH
Patients' Follow-up, conducted in 1996-2001, patients could continue,
stop, or start hydroxyurea. Data were collected during the trial and in
the follow-up period.SettingInpatients and outpatients in 21 sickle cell referral
centers in the United States and Canada.PatientsTwo-hundred ninety-nine adult patients with frequent
painful episodes enrolled in the follow-up. Follow-up data through
May 2001 were complete for 233 patients.InterventionIn the MSH, patients were randomly assigned to
receive hydroxyurea (n = 152) or placebo (n = 147).Main Outcome MeasureMortality, HbF levels, painful episodes,
acute chest syndrome, and blood cell counts. The randomized trial was
not designed to detect specified differences in mortality.ResultsSeventy-five of the original 299 patients died, 28% from
pulmonary disease. Patients with reticulocyte counts less than
250 000/mm3 and hemoglobin levels lower than 9 g/dL
had increased mortality (P = .002).
Cumulative mortality at 9 years was 28% when HbF levels were lower
than 0.5 g/dL after the trial was completed compared with 15% when HbF
levels were 0.5 g/dL or higher
(P = .03 ). Individuals who had acute
chest syndrome during the trial had 32% mortality compared with 18%
of individuals without acute chest syndrome
(P = .02). Patients with 3 or more
painful episodes per year during the trial had 27% mortality compared
with 17% of patients with less frequent episodes
(P = .06). Taking hydroxyurea was
associated with a 40% reduction in mortality
(P = .04) in this observational follow-up with
self-selected treatment. There were 3 cases of cancer, 1 fatal.ConclusionsAdult patients taking hydroxyurea for frequent painful
sickle cell episodes appear to have reduced mortality after 9 of years
follow-up. Survival was related to HbF levels and frequency of
vaso-occlusive events. Whether indications for hydroxyurea treatment
should be expanded is unknown.
839 citations
••
Harvard University1, University of Minnesota2, Universidade Federal do Rio Grande do Sul3, Russian National Research Medical University4, New York Methodist Hospital5, Université de Montréal6, University of Washington7, Northwestern University8, University of Wisconsin-Madison9, University of Michigan10
TL;DR: This post hoc analysis demonstrated greater potassium and creatinine changes and possible clinical benefits with spironolactone in patients with heart failure and preserved ejection fraction from the Americas.
Abstract: Background—Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection fraction assigned to spironolactone did not achieve a significant reduction in the primary composite outcome (time to cardiovascular death, aborted cardiac arrest, or hospitalization for management of heart failure) compared with patients receiving placebo. In a post hoc analysis, an ≈4-fold difference was identified in this composite event rate between the 1678 patients randomized from Russia and Georgia compared with the 1767 enrolled from the United States, Canada, Brazil, and Argentina (the Americas). Methods and Results—To better understand this regional difference in clinical outcomes, demographic characteristics of these populations and their responses to spironolactone were explored. Patients from Russia/Georgia were younger, had less atrial fibrillation and diabetes mellitus, but were more likely to have had prior myocardial i...
732 citations
Authors
Showing all 953 results
Name | H-index | Papers | Citations |
---|---|---|---|
Manish Sharma | 82 | 1407 | 33361 |
Vic Hasselblad | 80 | 215 | 24087 |
Alan B. Lumsden | 69 | 490 | 16111 |
Kutluk Oktay | 68 | 261 | 16787 |
David J. Whellan | 60 | 269 | 16592 |
James C. Fang | 59 | 275 | 20075 |
Ralph Green | 54 | 228 | 10318 |
Sorin J. Brener | 47 | 266 | 13534 |
Ralph Carmel | 46 | 139 | 6949 |
S. Chiu Wong | 45 | 165 | 11468 |
O. Wayne Isom | 45 | 102 | 7446 |
Martin Möckel | 43 | 286 | 7630 |
Narong Kulvatunyou | 37 | 217 | 4691 |
Moshe Schein | 35 | 164 | 4528 |
Leslie Wise | 35 | 234 | 4783 |